American Journal of Preventive Medicine
Volume 16, Issue 2 , Pages 116-121 , February 1999

Preventing morbidity and mortality from sickle cell disease: A public health perspective

  • Richard S Olney, MD, MPH

      Affiliations

    • Birth Defects and Genetic Diseases Branch, Division of Birth Defects and Developmental Disabilities, National Center for Environmental Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA
    • Corresponding Author InformationAddress correspondence and reprint requests to: Richard S. Olney, MD, MPH, Stanford University School of Medicine, Department of Pediatrics, Division of Medical Genetics, H-315, 300 Pasteur Drive, Stanford, CA 94305-5208

References 

  1. Lane PA. Sickle cell disease. Pediatr Clin North Am. 1996;43:639–664
  2. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997;337:762–769
  3. Serjeant GR. Sickle-cell disease. Lancet. 1997;350:725–730
  4. Davies SC, Oni L. Management of patients with sickle cell disease. BMJ. 1997;315:656–660
  5. Rodgers GP. Overview of pathophysiology and rationale for treatment of sickle cell anemia. Semin Hematol. 1997;34(3 Suppl 3):2–7
  6. Serjeant GR. Sickle cell disease, 2nd ed. New York: Oxford University Press; 1992;
  7. Embury SH, Hebbel RP, Mohandas N, Steinberg MH. Sickle cell disease (Basic principles and clinical practice). New York: Raven Press; 1994;
  8. Reid CD, Charache S, Lubin B, eds. Management and therapy of sickle cell disease, 3rd ed. Bethesda: National Institutes of Health, 1995; NIH publication no. 96-2117.
  9. WHO Working Group . Community control of hereditary anaemias (memorandum from a WHO meeting). Bull World Health Org. 1983;61:63–80
  10. Forget BG. Molecular genetics of human hemoglobin synthesis. Ann Internal Med. 1979;91:605–616
  11. Sears DA. The morbidity of sickle cell trait (a review of the literature). Am J Med. 1978;64:1021–1036
  12. Serjeant GR. The sickle cell trait. In: Sickle cell disease, 2nd ed. New York: Oxford University Press, 1992;415–25.
  13. Zarkowsky HS, Gallagher D, Gill FM, et al.  Bacteremia in sickle hemoglobinopathies. J Pediatr. 1986;109:579–585
  14. Platt OS, Brambilla DJ, Rosse WF, et al.  Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639–1644
  15. Reid CD, Charache S, Lubin B, eds. Management and therapy of sickle cell disease, 3rd ed. Bethesda: National Institutes of Health, 1995:29-33; NIH publication no. 96-2117.
  16. Gill FM, Sleeper LA, Weiner SJ, et al.  Clinical events in the first decade in a cohort of infants with sickle cell disease. Blood. 1995;86:776–783
  17. Powars DR. Beta-S-gene-cluster haplotypes in sickle cell anemia. Clinical and hematologic features. Hematol Oncol Clin North Am. 1991;5:475–493
  18. Charache S, Terrin ML, Moore RD, et al.  Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332:1317–1322
  19. Khoury MJ, Beaty TH, Cohen BH. Applications of genetic epidemiology in medicine and public health. In: Fundamentals of genetic epidemiology. New York: Oxford University Press; 1993;p. 324–325
  20. Nickens H. The genome project and health services for minority populations. In:  Murray TH,  Rothstein MA,  Murray RE editor. The human genome project and the future of health care. Bloomington, IN: Indiana University Press; 1996;p. 58–78
  21. Bobinski MA. Genetics and reproductive decision making. In:  Murray TH,  Rothstein MA,  Murray RE editor. The human genome project and the future of health care. Bloomington, IN: Indiana University Press; 1996;p. 79–112
  22. American Academy of Pediatrics Committee on Genetics . Health supervision for children with sickle cell diseases and their families. Pediatrics. 1996;98:467–472
  23. Serjeant GR. The role of preventive medicine in sickle cell disease. The Watson Smith lecture. J R Coll Physicians Lond. 1996;30:37–41
  24. Platt OS, Guinan EC. Bone marrow transplantation in sickle cell anemia—the dilemma of choice. N Engl J Med. 1996;335:426–428
  25. Schechter AN, Rodgers GP. Sickle cell anemia—basic research reaches the clinic. N Engl J Med. 1995;332:1372–1374
  26. Sickle Cell Disease Guideline Panel. Sickle cell disease: screening, diagnosis, management, and counseling in newborns and infants. Clinical practice guideline no. 6. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, 1993; AHCPR publication no. 93-0562.
  27. Gaston MH, Verter JI, Woods G, et al.  Prophylaxis with oral penicillin in children with sickle cell anemia (a randomized trial). N Engl J Med. 1986;314:1593–1599
  28. Consensus conference . Newborn screening for sickle cell disease and other hemoglobinopathies. JAMA. 1987;258:1205–1209
  29. Pearson HA. Neonatal testing for sickle cell diseases—a historical and personal review. Pediatrics. 1989;83(5 Pt 2):815–818
  30. Harris MS, Eckman JR. Georgia’s experience with newborn screening (1981 to 1985). Pediatrics. 1989;83(5 Pt 2):858–860
  31. American Academy of Pediatrics Committee on Genetics . Newborn screening fact sheets. Pediatrics. 1996;98:473–501
  32. Steele RW, Warrier R, Unkel PJ, et al.  Colonization with antibiotic-resistant Streptococcus pneumoniae in children with sickle cell disease. J Pediatr. 1996;128:531–535
  33. Teach SJ, Lillis KA, Grossi M. Compliance with penicillin prophylaxis in patients with sickle cell disease. Arch Pediatr Adolesc Med. 1998;152:274–278
  34. Centers for Disease Control and Prevention . Defining the public health impact of drug-resistant Streptococcus pneumoniae (report of a working group). MMWR. 1996;45(No. RR-1):1–20
  35. John AB, Ramlal A, Jackson H, et al.  Prevention of pneumococcal infection in children with homozygous sickle cell disease. BMJ. 1984;288:1567–1570
  36. Emond AM, Collis R, Darvill D, et al.  Acute splenic sequestration in homozygous sickle cell disease (natural history and management). J Pediatr. 1985;107:201–206
  37. Vichinsky E, Hurst D, Earles A, et al.  Newborn screening for sickle cell disease (effect on mortality). Pediatrics. 1988;81:749–755
  38. Boswell DH. Fund-raising methods and special community programs for sickle cell anemia. In:  Olafson F,  Parker AW editor. Sickle cell anemia—the neglected disease (Community approaches to combating sickle cell anemia). Berkeley: University Extension, University of California; 1973;p. 78–81
  39. Kan YW, Dozy AM, Alter BP, et al.  Detection of the sickle gene in the human fetus. Potential for intrauterine diagnosis of sickle-cell anemia. N Engl J Med. 1972;287:1–5
  40. Fischel-Ghodsian N. Prenatal diagnosis of hemoglobinopathies. Clin Perinatology. 1990;17:811–828
  41. Bowman JE. Legal and ethical issues in newborn screening. Pediatrics. 1989;83(5 Pt 2):894–896
  42. Bowman JE. Prenatal screening for hemoglobinopathies. Am J Hum Genet. 1991;48:433–438
  43. Committee on Technical Bulletins of the American College of Obstetricians and Gynecologists. ACOG technical bulletin. Hemoglobinopathies in pregnancy. Number 220–February 1996 (replaces no. 185, October 1993). Int J Gynaecol Obstet 1996; 53:184–94.
  44. Granda H, Gispert S, Martinez G, et al.  Results from a reference laboratory for prenatal diagnosis of sickle cell disorders in Cuba. Prenat Diagn. 1994;14:659–662
  45. Wang X, Seaman C, Paik M, et al.  Experience with 500 prenatal diagnoses of sickle cell diseases (the effect of gestational age on affected pregnancy outcome). Prenat Diagn. 1994;14:851–857
  46. Rowley PT, Loader S, Sutera CJ, et al.  Prenatal screening for hemoglobinopathies. I. A prospective regional trial. Am J Hum Genet. 1991;48:439–446
  47. National Sickle Cell Anemia Control Act. Pub. L. No. 92-294, 86 Stat. 138 (May 16, 1972).
  48. Illinois Administrative Code. Title 77, Chapter 1, Subchapter i, Section 661.50 (1995).
  49. Centers for Disease Control. Sickle cell disease and other hemoglobinopathies. Infant Screening Quality Assurance Program Performance Surveillance Quarterly Report (Sickle Cell Disease and Other Hemoglobinopathies), vol. 2, no. 1. Atlanta: Centers for Disease Control, 1992.
  50. Center for Disease Control. Advanced laboratory methods of hemoglobinopathy detection. 3rd ed. Atlanta: U. S. Dept. of Health, Education, and Welfare, Public Health Service, Center for Disease Control, Bureau of Laboratories, Hematology Division, 1976; DHEW publication no. (CDC) 76-8296.
  51. U.S. Department of Health and Human Services. Healthy people 2000: national health promotion and disease prevention objectives. Washington, DC: U.S. Government Printing Office, 1991:111; DHHS Publication no. (PHS) 91-50213.
  52. U.S. Preventive Services Task Force. Guide to clinical preventive services: report of the U.S. Preventive Services Task Force, 2nd ed. Baltimore: Williams & Wilkins, 1996:485–94.
  53. Tsevat J, Wong JB, Pauker SG, et al.  Neonatal screening for sickle cell disease (A cost-effectiveness analysis). J Pediatr. 1991;118(4 Pt 1):546–554
  54. Sprinkle RH, Hynes DM, Konrad TR. Is universal hemoglobinopathy screening cost-effective?. Arch Pediatr Adolesc Med. 1994;148:461–469
  55. Gessner BD, Teutsch SM, Shaffer PA. A cost-effectiveness evaluation of newborn hemoglobinopathy screening from the perspective of state health care systems. Early Hum Dev. 1996;45:257–275
  56. Lane PA, Eckman JR. Cost-effectiveness of neonatal screening for sickle cell disease. J Pediatr. 1992;120:162–163
  57. Davis H, Schoendorf KC, Gergen PJ, et al.  National trends in the mortality of children with sickle cell disease, 1968 through 1992. Am J Public Health. 1997;87:1317–1322
  58. Leikin SL, Gallagher D, Kinney TR, et al.  Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. Pediatrics. 1989;84:500–508
  59. Centers for Disease Control and Prevention . Mortality among children with sickle cell disease identified by newborn screening during 1990–1994—California, Illinois, and New York. MMWR. 1998;47:169–172
  60. Davis H, Moore RMJ, Gergen PJ. Cost of hospitalizations associated with sickle cell disease in the United States. Public Health Rep. 1997;112:40–43
  61. Yoon PW, Olney RS, Khoury MJ, et al.  Contribution of birth defects and genetic diseases to pediatric hospitalizations (a population-based study). Arch Pediatr Adolesc Med. 1997;151:1096–1103
  62. Wilimas JA, Flynn PM, Harris S, et al.  A randomized study of outpatient treatment with ceftriaxone for selected febrile children with sickle cell disease. N Engl J Med. 1993;329:472–476
  63. Serjeant GR. Historical Aspects. In: Sickle cell disease. 2nd ed.. New York: Oxford University Press; 1992;p. 71–77
  64. Neel JV. Physician to the gene pool (genetic lessons and other stories). New York: John Wiley & Sons; 1994;

PII: S0749-3797(98)00140-8

American Journal of Preventive Medicine
Volume 16, Issue 2 , Pages 116-121 , February 1999

Article Tools